# Exelixis

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/exelixis/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | American biotechnology company |
| OpenAlex ID | https://openalex.org/F4320312140 |
| ROR ID | https://ror.org/01e3jga91 |
| Works | 2,402 |

## Funder papers

- [<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes](https://scholariq.org/papers/i-egfr-i-mutant-adenocarcinomas-that-transform-to-small-cell-lung-cancer-and/)
- [Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study](https://scholariq.org/papers/durvalumab-in-combination-with-olaparib-in-patients-with-relapsed-sclc-results/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.